Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
11 search results for:

Probenecid 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 05-03-2018 | Gout | News | Article

    Probenecid may have cardioprotective effects in patients with gout

    Results of a large observational study suggest that older patients with gout who are treated with probenecid may have a lower risk for cardiovascular events than those taking allopurinol.

    Published in:
    J Am Coll Cardiol 2018; 71 : 994–1004, 1005–1008
  2. 02-02-2022 | Gout | News | Article

    Gout linked to increased risk for lower extremity amputation

    Specifically, having suboptimal urate levels (average >7 mg/dL in each year of follow-up) was associated with a significant 26% increased LEA risk for people with suboptimal ULT (no receipt of allopurinol, febuxostat, or probenecid for at least 90 days per year), and a 37% increased risk for those with adequate or indeterminate ULT.

    Author:
    Claire Barnard
    Published in:
    JAMA Netw Open 2022; 5 : e2142347
  3. 03-02-2021 | Rheumatoid arthritis | News | Article

    Potential drug–drug interactions with JAK inhibitors may be going unrecognized

    A further 3.16% of patients had claims for strong CYP3A4 inhibitors alone (namely clarithromycin), 1.00% of patients had claims for strong CYP3A4 and CYP2C19 inhibitors combined, and 0.06% of patients had claims for strong organic anion transporter 3 inhibitors alone, most commonly probenecid.

    Author:
    Hannah Kitt
    Published in:
    Rheumatol Ther 2021; doi:10.1007/s40744-020-00275-8
  4. 21-06-2018 | Gout | Review | Article

    Predicting response or non-response to urate-lowering therapy in patients with gout

    The authors review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy may be modified to increase the response in the majority of patients with gout. Graham GG et al. Curr Rheumatol Rep 2018; 20: 47. doi: 10.1007/s11926-018-0760-2

  5. 21-06-2018 | Gout | Highlight | Teaser
    Journal article

    Predicting response or non-response to urate-lowering therapy in patients with gout

    The authors review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy may be modified to increase the response in the majority of patients with gout [ read more ]. Graham GG et al. Curr Rheumatol Rep 2018; 20: 47. doi: 10.1007/s11926-018-0760-2

  6. 13-02-2018 | Gout | Review | Article

    Managing gout in the patient with renal impairment

    Pascual E, Sivera F, Andrés M. Drugs Aging 2018; Advance online publication. doi: 10.1007/s40266-018-0517-7

  7. 31-08-2017 | Gout | News | Article

    Lifestyle modification might improve ULT response in gout patients

    Most participants (83.8%) were male, and the majority of patients were prescribed allopurinol (71.7%), with the remainder taking febuxostat, probenecid, or benzbromarone.

    Published in:
    Arthritis Care Res 2017; Advance online publication
  8. 08-09-2016 | Gout | Article

    Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis

    However, probenecid ranked the worst for safety.

    Author:
    Shu Li, Hongxi Yang, Yanan Guo, Fengjiang Wei, Xilin Wang, Daiqing Li, Mingzhen Li, Weili Xu, Weidong Li, Li Sun, Ying Gao, Yaogang Wang
  9. 27-02-2015 | Gout | Review | Article

    Current and emerging therapies for gout

    The authors review some of the newer medications, which may become the future of gout therapy, including new urate-lowering therapies and new anti-inflammatory agents. Mohammad S, Giattino SL, & Keenan RT. Curr Treat Options in Rheum 2015;1:143–155. doi:10.1007/s40674-015-0015-6

  10. 29-09-2015 | Gout | Article

    Allopurinol hypersensitivity: investigating the cause and minimizing the risk

    For example, probenecid is a widely available drug that increases the excretion of uric acid in urine, but it is ineffective in those with kidney impairment; similarly, febuxostat is reportedly more effective than standard doses of allopurinol 57  but the availability of febuxostat in many countries is restricted to those patients who cannot tolerate, or fail to achieve target serum urate levels in response to, allopurinol.

    Author:
    Lisa K. Stamp, Richard O. Day, James Yun
  11. 26-09-2014 | Gout | Article

    Urate-lowering therapy: current options and future prospects for elderly patients with gout

    This paper discusses the use of urate-lowering therapies in elderly patients, with a focus on the available therapeutic options and their risks and benefits in this patient population, as well as a mention of pipeline therapeutics. Stamp LK, Chapman PT.  Drugs Aging . 2014;31:777–786. doi: 10.1007/s40266-014-0214-0.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.